Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

Autor: Beatrix Bartok, William B. Kiosses, Nikolaos Mitakidis, Nunzio Bottini, David L. Boyle, Jeffrey D. Esko, Mattias Svensson, Gary S. Firestein, Ru Liu-Bryan, Esther Cory, Camille Fos, Stephanie M. Stanford, Robert L. Sah, Tomas Mustelin, Heather A. Arnett, C.H. Coles, Michel L. Tremblay, Karen M. Doody, Maripat Corr, Cristiano Sacchetti, A. Radu Aricescu

Publikováno v: Science translational medicine 7(288), 288ra76-288ra76 (2015). doi:10.1126/scitranslmed.aaa4616
Science translational medicine, vol 7, iss 288

Despite the availability of several therapies for rheumatoid arthritis (RA) that target the immune system, a large number of RA patients fail to achieve remission. Joint-lining cells, called fibroblast-like synoviocytes (FLS), become activated during

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412744d5cefd3ee5f48ca9e47b78e31d